Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co Ltd is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the Chinese market.
Business. Hunan Jiudian Pharmaceutical Co Ltd (300705.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Hunan Jiudian Pharmaceutical Co Ltd (300705.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Hunan Jiudian Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a current ratio of 3.64, indicating that it has sufficient current assets to cover its current liabilities. However, the company reported negative net cash after subtracting total debt, which raises some liquidity concerns. The company's price-to-book ratio is 2.21, and its price-to-tangible-book ratio is also 2.21, suggesting that the market values the company at a premium to its book value.
In terms of profitability, the company's return on equity (ROE) is 17.78%, and its return on assets (ROA) is 11.77%, both of which are strong indicators of efficient use of equity and assets. The company's gross profit margin is 72.7%, and its operating margin is 17.1%, which are both above the industry median for pharmaceutical companies.
The company's revenue is primarily concentrated in its domestic market, with no significant international revenue disclosed in the latest financial data. Hunan Jiudian Pharmaceutical Co Ltd operates as a single business segment, and its geographic exposure is primarily within China.
Looking ahead, the company's revenue is expected to grow in the current fiscal year, with a positive outlook for the next fiscal year as well. However, the company's free cash flow is negative, at -218.68 million CNY, which may limit its ability to fund growth initiatives without external financing. The company's capital expenditure of -652.89 million CNY indicates a significant investment in long-term assets.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.25, indicating a relatively conservative capital structure. However, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the near term. No dilution sources were identified in the latest filings or transcripts.
Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial results were released in the most recent quarter, and no significant earnings surprises or regulatory actions were reported.
- Hunan Jiudian Pharmaceutical Co Ltd has a strong ROE of 17.78% and ROA of 11.77%, indicating efficient use of equity and assets.
- The company's liquidity position is strong, with a current ratio of 3.64, but its net cash position is negative after subtracting total debt.
- The company's price-to-book ratio of 2.21 suggests that the market values the company at a premium to its book value.
- Hunan Jiudian Pharmaceutical Co Ltd's revenue is primarily concentrated in its domestic market, with no significant international exposure.
- The company's free cash flow is negative, which may limit its ability to fund growth initiatives without external financing.
- The company's risk profile is characterized by a medium liquidity risk and a low dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Hunan Jiudian Pharmaceutical Co Ltd Market data — financials · 2026-05-26